ArticleJournal of the Royal Society, Interface2026
Bio-interfacial engineering of electrophoretic coacervate microcapsules for cytocompatible on-skin displays.
Article in Journal of the Royal Society, Interface, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Bio-interfacial engineering of electrophoretic coacervate microcapsules for cytocompatible on-skin displays.Journal of the Royal Society, Interface · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Electrophoretic ink (e-ink) holds significant potential for energy-efficient displays and sustainable alternatives to print media. However, their use in wearables is hindered by hazardous materials which are cytotoxic and sensitizing to human tissue. While commercial e-inks encapsulate these fluids in rigid, synthetic microplastics, such as melamine-formaldehyde, they lack the mechanical conformability and environmental safety required for epidermal contact. We thus present a novel approach for producing e-ink microcapsules (EIMCs) for integration into biocompatible and free-form digital devices. Spherical, core-shell EIMCs were fabricated via complex coacervation (pH 4.1), using user-friendly biopolymers (gum acacia and gelatin). A core of white electrophoretic TiO2 particles (diameter approx. 30 nm) was marked with a darker violet dye, while being homodispersed in hexylsalicylate-tetrachloroethylene (HS-PCE), as the liquid medium. Characterization of the physico-chemical and performance properties of EIMCs showed remarkable nominal compression stress at rupture (3.9 ± 0.9 MPa). When subjected to a DC voltage of 20 V, the microcapsules created a writable display, potentially enabling users to write and rewrite. The response time was approximately 0.5 seconds (2 Hz refresh rate), comparable to commercial products. In vitro cytotoxicity and CD54 expression (h-CLAT) assays demonstrated that the microcapsule shell successfully mitigated solvent-induced immunotoxicity, maintaining high cellular viability (approx. 70%) and minimal sensitization (approx. 1.7%).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.